



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
08/460,186	06/02/1995	REID VON BORSTEL	18010-CP7D1	5103

7590 06/16/2010
Lewis J. Kreisler
Wellstat Management Company, LLC
Legal Department
930 Clopper Road
Gaithersburg, MD 20878

EXAMINER

OLSON, ERIC

ART UNIT	PAPER NUMBER
----------	--------------

1623

MAIL DATE	DELIVERY MODE
-----------	---------------

06/16/2010

PAPER

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

Response to Rule 312 Communication	Application No.	Applicant(s)
	08/460,186	VON BORSTEL ET AL.
	Examiner	Art Unit
	ERIC S. OLSON	1623

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --

1. ☒ The amendment filed on 10 June 2010 under 37 CFR 1.312 has been considered, and has been:

a) ☐ entered.

b) ☒ entered as directed to matters of form not affecting the scope of the invention.

c) ☐ disapproved because the amendment was filed after the payment of the issue fee.

Any amendment filed after the date the issue fee is paid must be accompanied by a petition under 37 CFR 1.313(c)(1) and the required fee to withdraw the application from issue.

d) ☐ disapproved. See explanation below.

e) ☐ entered in part. See explanation below.

The amendment received June 10, 2010 amends the base claim 1, which previously recited "an acylated derivative of uridine selected from the group consisting of triacetyluridine and ethoxycarbonyluridine, or triacetylcytidine," by specifying that the derivative is a derivative of either uridine or cytidine. As the objective scope of the claim is directed to the same three compounds, triacetyluridine, ethoxycarbonyluridine, and triacetylcytidine, it makes no difference to the scope of the claim whether they are described as uridine or cytidine derivatives. Therefore the amendment is entered as it does not affect the scope of the previously allowed claims.

/Eric S Olson/
Examiner, Art Unit 1623